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G protein-coupled receptors (GPCRs) are notoriously difficult to detect in native tissues. In an
effort to resolve this problem, we have developed a novel mouse model by fusing the
hemagglutinin (HA)-epitope tag sequence to the amino-terminus of the µ-opioid receptor
(MOP). Although HA-MOP knock-in mice exhibit reduced receptor expression, we found that
this approach allowed for highly efficient immunodetection of low abundant GPCR targets.
We also show that the HA-tag facilitates both high-resolution imaging and immunoisolation
of MOP. Mass spectrometry (MS) confirmed post-translational modifications, most notably
agonist-selective phosphorylation of carboxyl-terminal serine and threonine residues. MS
also unequivocally identified the carboxyl-terminal 387LENLEAETAPLP398 motif, which is part
of the canonical MOP sequence. Unexpectedly, MS analysis of brain lysates failed to detect
any of the 15 MOP isoforms that have been proposed to arise from alternative splicing of the
MOP carboxyl-terminus. For quantitative analysis, we performed multiple successive rounds
of immunodepletion using the well-characterized rabbit monoclonal antibody UMB-3 that
selectively detects the 387LENLEAETAPLP398 motif. We found that >98% of HA-tagged MOP
contain the UMB-3 epitope indicating that virtually all MOP expressed in the mouse brain
exhibit the canonical amino acid sequence.
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S ince the initial cloning of the single-copy µ-opioid receptorgene (OPRM1), numerous isoforms resulting from alter-native mRNA splicing have been postulated in humans,
rats, and mouse1–3, however, their in vivo significance is largely
unknown. While at least 15 alternative MOP transcripts involve
carboxyl-terminal (C-terminal) variants, others are proposed to
form non-canonical receptors that no longer conform to the
7-transmembrane topology of classical GPCRs4,5. Most tran-
scripts have been solely identified at the RNA level and studies
into their functional significance usually employed in vitro
models of recombinantly-expressed receptor constructs6,7. Only a
few investigations ever attempted to verify the presence of MOP
isoforms at the protein level. For example, using polyclonal
antisera expression of two C-terminal MOP splice variants
(MOP1B4 and MOP1C) could be visualized in various areas of
the mouse brain3,8,9. Using a similar approach, the MOP1B splice
variant of the rat was detected in discrete brain areas10. However,
in none of these studies, polyclonal antisera were rigorously tested
in knockout tissues.
At the functional level, several attempts were made to match
specific isoforms with particular opioid compounds or link them
to selected physiological opioid effects. These studies mostly used
isoform-specific RNA knock-down approaches, suffering from
inherent limitations of unknown efficacy while working against a
background of abundantly expressed canonical receptors. One
study described co-expression of the murine MOP1D isoform
together with gastrin-releasing peptide receptors in lamina 1 of
the spinal cord and their co-involvement in morphine-induced
itch11. To date, at least 30 C-terminal MOP splice variants have
been postulated (mouse, rat, human) based on mRNA sequencing
data, out of which 15 are of murine origin. Noteworthy, 11 of
these 15 murine transcripts have been published by a single
lab12–14.
In general, the lack of validated high-affinity antibodies and the
low abundance of MOP protein expression in native tissues have
made it difficult to conclusively verify the existence of postulated
variant MOP isoforms. Earlier attempts to address this problem
involved a transgenic model expressing a fusion of red fluorescent
protein to the C terminus of MOP, harboring the risk of inter-
ference with intracellular signaling15. Hemagglutinin (HA)-MOP
transgenic mice overcome these limitations and allow for the first
time isolation of native MOP proteins from tissues. By design of
the transgenic construct, HA-MOP allows for the identification of
any C-terminal variants. In this study, we used mass spectrometry
(MS) to directly identify MOP C-terminal variants and differ-
ential agonist-dependent phosphorylation states of native HA-
MOP receptors. Our results suggest that C-terminal variants of
MOP either do not exist or occur at such low abundance that
their physiological significance is questionable.
Results
Characterization of HA-MOP knockin mice. We generated a
novel transgenic mouse model by fusing the HA-epitope tag
sequence YPYDVPDYA to the amino-terminus of MOP (HA-
MOP) (Fig. 1a and Supplementary Fig. 1). HA-MOP knockin
mice were viable and healthy and showed no differences in body
weight and basal pain response (Supplementary Fig. 2d, e).
Binding affinity (Kd) of [3H]DAMGO determined in saturation
binding studies using brain membranes was not changed between
wild-type (WT) and HA-MOP mice (Supplementary Fig. 2a).
However, the total number of receptors (Bmax) was significantly
decreased by about 50% in the brain from HA-MOP mice
(Supplementary Fig. 2b). Similar results were obtained by quan-
titative autoradiography of [3H]DAMGO binding in the nucleus
accumbens, thalamus, hypothalamus, amygdala, and
somatosensory cortex (Supplementary Fig. 2c). Furthermore,
DAMGO-stimulated [35S]GTPγS binding is significantly
decreased in HA-MOP brain membranes compared to wild-type,
both in potency (EC50) and efficacy (% stimulation). Accordingly,
HA-MOP knockin mice exhibit reduced antinociceptive respon-
ses to morphine, which are similar to heterozygous MOP
knockout (MOP+/−) mice (Supplementary Fig. 2f). In order to
confirm MOP expression in native mouse tissues, we first
immunoprecipitated HA-MOP from whole-brain lysates using
anti-HA magnetic beads (Fig. 1b). HA-MOP was detected in
western blots using both an anti-HA antibody directed to the
N-terminal tag (Fig. 1b, left panel) as well the well-characterized
UMB-3 antibody directed to the carboxyl-terminal tail of the
canonical MOP receptor (Fig. 1b, right panel), while no band was
detected in WT mice. Next, we evaluated HA-MOP expression
levels in different organs (Fig. 1c). The highest levels of HA-MOP
expression were found in the brain and spinal cord, as well as in
the gastrointestinal tract. Furthermore, we also detected moderate
HA-MOP expression in the heart, thymus, spleen, and uterus.
HA-MOP expression was not detectable in lysates prepared from
lung, liver, pancreas, or kidneys. We then prepared brain slices
from adult mice and examined HA-MOP expression in different
brain regions using immunohistochemistry (Figs. 1 and 2). As
shown in Fig. 1d, immunostaining for HA-MOP was detected in
the striatum (CPu) of knockin mice but not in WT mice. At high
resolution, HA-MOP was detectable on habenula neuronal cell
bodies, as well as cell bodies and dendrites of amygdala neurons.
Next, we analyzed HA-MOP expression at different develop-
mental stages. The HA-MOP was first detectable at E16 and
expression increases until birth. Slices from postnatal mice at P7
and P10 already show the typical MOP expression pattern of
adult striatum.
MOP phosphorylation pattern in vivo. Agonist-dependent MOP
phosphorylation plays a major role in receptor desensitization
and downstream signaling. To analyze the different phosphor-
ylation patterns (involving S375, T370, T376, and T379) in native
tissues, we administered various clinically relevant MOP agonists
including the MOP antagonist naltrexone and saline as controls
(Fig. 3). All MOP agonists induced strong MOP phosphorylation
at S375 detected using phosphosite-specific antibodies. However,
the MOP partial agonists morphine and oxycodone were not able
to promote higher-order phosphorylation at additional phospho-
acceptor sites. All high-efficacy agonists such as methadone,
fentanyl, sufentanil, or etonitazene promoted robust receptor
phosphorylation at T370, T376, and T379 in addition to S375. No
signals were detected after naltrexone or saline treatment. The MS
analysis confirmed that peptides from the HA-MOP carboxyl-
terminus were phosphorylated in the agonist-stimulated condi-
tions, but not in the control conditions (Table 1). The peptide
349EFCIPTSSTIEQQNSAR365 phosphorylated on S363 was
identified in samples from mice treated with fentanyl and eto-
nitazene. Single phosphorylation on T370 and double phos-
phorylation on T370/S375 or T370/T376, were unequivocally
identified on the peptide 366IRQNTREHPSTANTVDR382 and the
shorter form 368QNTREHPSTANTVDR382 in the three agonist-
treated conditions. However, the triple phosphorylation at T370/
S375/T376 was only observed after treatment with the high-
efficacy agonist etonitazene. These results confirm and extend
previous in vitro and in vivo studies demonstrating hierarchical
and agonist-selective phosphorylation of the MOP carboxyl-
terminal tail, indicating that the HA-MOP mouse model is a valid
tool for biochemical characterization of endogenously expressed
µ-opioid receptors.
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Investigation of alternative MOP splice variants in vivo. In
order to identify peptides belonging to the different putative
MOP isoforms, anti-HA-immunoprecipitated samples from
control and three agonist-treated conditions were subjected to
SDS-PAGE separation. HA-MOP corresponding bands were in-
gel digested for further analysis by nano–liquid chromatography-
tandem MS (nanoLC–MS/MS). NanoLC–MS/MS identified 4
peptides located in the carboxyl-terminal domain of the MOP
receptor, covering positions 349 to 398 of the canonical MOP
sequence (Tables 1 and 2, green color, Supplementary Table 1).
An additional peptide covering positions 166 to 174 located in
close proximity to the DRY motif at the end of TM3 was also
identified. Nevertheless, no putative peptide corresponding to any
of the non-canonical isoforms of the MOP carboxyl-terminus
(Table 2, blue color) was identified by MS. Only the C-terminal
sequence 387LENLEAETAPLP398 that is defining the canonical
MOP isoform was identified in all samples, suggesting that
alternatively spliced species of MOP were either absent or present
at a very low level in whole-brain extracts. However, it should be
noted that a few of the putatively generated C-terminal tryptic
peptides would have an amino acid length <7 that could poten-
tially exclude them from MS detection.
In another set of experiments, we performed a series of
successive immunodepletions in an attempt to enrich HA-MOP
variants containing non-canonical C termini (Fig. 4). As shown in
Fig. 4b, three rounds of immunodepletion with anti-HA were
sufficient to remove all HA-MOP proteins from the whole brain
lysate, demonstrating the high affinity and capacity of the
antibody. Serial depletion of MOP receptors containing the
canonical C terminus, which is selectively recognized by the
Fig. 1 Localization and phosphorylation of HA-MOP in mouse brain. a Schematic representation of the N-terminally tagged HA-MOP and the C-terminal
tail with potential phosphorylation sites (black: antibody detectable phosphorylation sites; light gray: possible phosphorylation sites). b Western blot
analysis of brain lysates from HA-MOP mice compared to wild-type animals after immunoprecipitation with anti-HA magnetic beads. Proteins were either
immunoblotted with anti-HA antibody (left panel) or UMB-3 (right panel). c Western blot analysis of HA-MOP expression in different organs. Blots are
representative of three independent experiments. d 40 µm brain section of an adult HA-MOP mouse (right panel) compared to wild-type (left panel).
Slices were stained with Cy3-labeled (550 nm) secondary antibody and pseudo-colored afterward. e Developmental expression of HA-MOP in mouse
striatum across different age stages. 40 µm brain slices were stained with anti-HA antibody followed by Cy3-labeled secondary antibody and pseudo-
colored afterward. d, e Scale bar = 1000 µm. CPu caudate putamen.
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rabbit monoclonal antibody UMB-3, removed most of HA-MOP
after four rounds of precipitation (Fig. 4c). However, a very low
level of HA-MOP immunopositive material remained in the
lysate that could not be further depleted by additional rounds of
immunoprecipitation (Fig. 4c, upper panel, precipitation rounds
6-8). A calibration standard using a serial dilution of total UMB-3
precipitated HA-MOP protein indicated that the remaining non-
precipitable material corresponds to ∼2% of total HA-MOP
(Fig. 4c, upper and lower panel). These experiments indicate that
virtually all µ-opioid receptors in brain lysates from HA-MOP
knockin mice exhibit the canonical amino acid sequence.
MOP1D splice variant. MOP1D, also designated isoform-9, is
one of the most established splice variants with several publica-
tions over the last years. A physiological function has been pos-
tulated as a receptor that specifically mediates morphine-
associated itch11,16. Given that MOP1D is one of the isoforms
that are difficult to detect by MS because of small predicted
tryptic peptides at the C terminus, we generated a MOP1D-
selective antibody. To address the question of whether MOP1D is
expressed in the brain, we compared homogenized brain lysates
from HA-MOP mice to HEK293 cells, which stably express HA-
MOP1D in western blots after immunoprecipitation with anti-
HA antibody beads (Fig. 5a). MOP1D was readily detected in
transfected HEK293 cells (Fig. 5b, left panel) but was absent from
mouse brain lysates. Conversely, canonical HA-MOP could be
detected in brain lysates but not in MOP1D-expressing cells using
UMB-3 that specifically detects the carboxyl-terminal 387LEN-
LEAETAPLP398 motif, which is part of the canonical MOP
sequence (Fig. 5b, middle panel). Both isoforms were readily
detected using the anti-HA antibody (Fig. 5b, right panel).
MOP1D immunohistochemistry also failed to detect any MOP1D
splice variant in the brain, spinal cord, or DRGs.
Discussion
For all members of the opioid receptor family, transgenic mouse
models have been created, in which relatively large fluorescent
proteins were fused to the carboxyl terminus of the
receptor15,17–19. While these models have proven useful to
visualize the cellular receptor expression, all these models
inherently harbor the risk of interference of the bulky carboxyl-
terminal tag with post-translational modifications such as phos-
phorylation or essential protein-protein interactions, including
GRKs (G protein-coupled receptor kinases), arrestins, and G
proteins. One study used a conventional transgenic approach to
create an N-terminally FLAG-tagged MOP mouse model and
analyzed receptor desensitization and trafficking in locus coer-
uleus (LC) neurons20. However, the transgene used a tyrosine
hydroxylase promoter (in order to drive expression in LC)
whereas our approach is based on the targeted insertion of the tag
into the endogenous mOPRM1 gene, which should preserve
native expression patterns. This strategy is in line with the
recently published FLAG-tagged DOP21 and HA-tagged DOP22
receptor mouse models that used targeted recombination. In an
effort to solve this problem, we have developed a novel mouse
model by fusing the HA-epitope tag sequence to the amino ter-
minus of the MOP. Herein, we provide evidence that this
approach offers a powerful means for highly efficient immuno-
detection of MOP in native tissues. The HA-tag greatly facilitated
immunoisolation of MOP and MS analyses confirmed post-
translational modifications in vivo. Furthermore, we demonstrate
agonist-dependent phosphorylation of native MOP proteins in
neuronal tissue, harnessing the enhanced detection sensitivity
gained by the transgenic approach.
Insertion of the N-terminal HA-tag into MOP does not impact
the binding affinity of the receptor but significantly reduces HA-
MOP expression levels in most brain regions. This also results in
a reduced antinociceptive response to morphine in HA-MOP
Fig. 2 Immunostaining for HA-MOP. a, b HA-MOP localization on cell bodies of habenula neurons (10× and 63× lenses). c 40 µm brain sections from
adult HA-MOP mouse compared to wild-type. d Cell bodies and dendrites in the amygdala (25× lenses). cSlices were stained with Cy3-labeled (550 nm)
secondary antibody and pseudo-colored afterward. Scale bars as indicated in each picture. MHb medial habenula, PAA piriform-amygdalar area.
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knockin mice, which is similar to that observed in heterozygous
MOP knockout mice23.
Agonist-dependent multi-side phosphorylation of HA-MOP
in vivo confirmed earlier experiments and recent publications on
MOP phosphorylation and downstream signaling24,25, while also
demonstrating the functionality of the C-terminal part of the
receptor. Previous studies using UMB-3 immunoprecipitation
had identified agonist-dependent phosphorylation at T370 and
S37526, while the HA-MOP knockin mouse model showed
additional phosphorylation at T376 by high-efficacy agonists,
analogous to prior in vitro experiments. Therefore, this novel
mouse model will greatly facilitate investigations into in vivo
receptor modifications as a function of high or low efficacy
agonists, duration of opioid exposure, and their possible corre-
lation with aversive opioid effects such as tolerance or respiratory
depression.
While earlier studies already proved the expression of MOP
mRNA at different prenatal stages of the mouse brain27, with this
new mouse model we were able to stain the expressed HA-tagged-
protein in the CPu of the embryonic brain, starting at E16 and
proceeding until P10, when there is an almost fully developed
pattern of MOP in the striatum, similar to the expression that can
be observed in adult mice.
Almost since the initial cloning of the opioid receptors in the
early 90s, reports on alternative splice variants have raised hopes
that such receptor isoforms may help explain particular physio-
logical effects of opioid drugs. However, almost none of these
numerous studies addressed the fundamental questions of
quantitative significance and actual expression at the protein level
of the alternative transcripts. A few studies used polyclonal
antisera generated against predicted alternative MOP C
termini3,11, but none of the antisera was rigorously validated in
knockout or specific transgenic mice.
We addressed the open debate about the existence of MOP
isoforms containing alternative C termini from two different
angles: (1) by amino acid sequencing via LC–MS/MS analysis of
precipitated HA-MOP, and (2) by immunodepletion of MOP
containing the canonical C terminus in order to enrich non-
canonical isoforms. Both approaches failed to produce conclusive
evidence for significant quantities of MOP isoforms with alter-
native C termini. The immunodepletion experiments indicate
that non-canonical MOP receptor proteins may constitute—at
best—<2% of total MOP receptors in the mouse brain and that
alternatively spliced MOP transcripts may represent hetero-
nuclear mRNA that is either not or poorly translated. Such a low
abundance of MOP with non-canonical C termini is in line with
the non-detection of any corresponding peptides in the LC–MS/
MS analysis. However, it should be noted that the predicted
tryptic hexapeptide of the postulated MOP1D C terminus might
elude MS detection, because of its small size. Therefore in a third
approach, we specifically investigated protein levels of the pos-
tulated MOP1D isoform by using a novel anti-MOP1D antibody.
Again, these experiments failed to demonstrate any significant
presence of MOP1D protein in total anti-HA-MOP precipitates.
This combination of experimental approaches strongly suggests
that predicted MOP isoforms with alternatively spliced C termini
either do not exist in mouse brain or are present at such low levels
that put their physiological significance into question.
In summary, the HA-MOP transgenic mouse model represents
a valuable tool to study protein expression and activity-dependent
modifications of MOP in vivo by greatly increasing the sensitivity
of protein detection. MOP isoforms with alternative C termini
may not exist at the protein level or are present at insignificant
levels. It is therefore questionable, how such a small amount of
alternative receptor protein isoforms may influence the overall
functionality of MOP signaling in the CNS or other organs with
even lower MOP expression levels.
Material and methods
Animals. Knock-in mice expressing HA-MOP (Oprm1em1Shlz,
MGI:6117675) were generated by Applied StemCell (Menlo Park,
USA), using CRISPR/Cas9-mediated targeted recombination.
Mice were genotyped by PCR from genomic tail-biopsy DNA
using the following primers: 5′-TACCCATACGATGTTCCA
GATTACGCT-3′ (mOprm1F) and 5′-GGAACTAGGTATTCA
GAACATGCCTTACCTTAC-3′ (mOprm1R), followed by RsaI
restriction to detect the presence of the HA-tagged mOprm1 gene
(Supplementary Fig. 1). All HA-MOP mice were backcrossed to
Fig. 3 MOP phosphorylation pattern in vivo. HA-MOP mice were either
treated with different MOP agonists, naltrexone, or saline. Western blots of
brain lysates immunoblotted with anti-pThr370 (first panel), anti-pS375
(second panel), anti-pThr376 (third panel), or anti-pThr379 (fourth panel)
antibodies. Blots were stripped and reprobed with a UMB-3 antibody to
control for equal loading. Positions of molecular mass markers are indicated
on the left (in kDa). Blots are representative of four independent
experiments.
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JAXTM C57Bl/6J obtained from Charles River Laboratories (DE)
which were also used for breeding of mutant strains and served as
controls in all experiments. Animals were housed 2–5 per cage
under a 12-hr light-dark cycle with ad libitum access to food and
water. All animal experiments were performed in accordance with
relevant guidelines and regulations, were approved by Thuringian
state authorities, and complied with European Commission reg-
ulations for the care and use of laboratory animals. Our study is
reported in accordance with the ARRIVE (Animal Research:
Reporting In Vivo Experiments) guidelines28. In all experiments,
male and female mice aged 8–30 weeks between 25 and 35 g body
weight were used.
Drugs and routes of administration. All drugs were freshly
prepared prior to use and were injected subcutaneously in lightly
restrained, unanaesthetized mice at a volume of 10 μl−1 body-
weight. Drugs were diluted in 0.9% (W/V) saline for injections.
Drugs were obtained and used as follows: morphine sulfate
(30 mg kg−1 for 30 min; Hameln Inc., Hameln, Germany), oxy-
codone hydrochloride (15 mg kg−1 for 30 min; Mundipharma
GmbH, Limburg, Germany), levomethadone hydrochloride
(15 mg kg−1 for 30 min; Sanofi-Aventis, Frankfurt, Germany),
sufentanil (30 mg kg−1 for 15 min; Hameln Inc., Hameln, Ger-
many), fentanyl citrate (0.3 mg kg−1 for 15 min; Rotexmedica,
Trittau, Germany), etonitazene (30 mg kg−1 for 30 min; Sigma-
Aldrich, Munich, Germany) and naltrexone hydrochloride
(10 mg kg−1 overnight; Neuraxpharm, Langenfeld, Germany).
Reagents and antibodies. Pierce™ Anti-HA Magnetic Beads were
obtained from Thermo Fisher Scientific (Schwerte, Germany),
while the phosphorylation-independent antibodies were obtained
as follows: rabbit monoclonal anti-HA antibody (Cell Signaling,
Frankfurt, Germany), and anti-MOP antibody {UMB-3} (Epi-
tomics, Burlingame, CA); used as previously described29. The
Table 1 MS analysis of agonist-induced phosphorylation sites in the MOP carboxy-terminus.
Peptide sequence Peptide position MH+ [Da] # Missed
cleavages
Best Mascot ion score
Best phosphoRS site probability (%)
Phosphosite
position
Saline Morphine Fentanyl Etonitazene
YIAVCHPVK 166-174 1086.5765 0 41 43 45 47
EFCIPTSSTIEQQNSAR 349-365 1967.9127 0 48 83 74 75
EFCIPTSSTIEQQNSAR 349-365 2047.8791 0 60 53
S363 100 100
IRQNTREHPSTANTVDR 366-382 2074.9778 2 44 43
T370 100 100
IRQNTREHPSTANTVDR 366-382 2154.9441 2 22 38
T370; S375 99.99; 49.79 100; 95.64
IRQNTREHPSTANTVDR 366-382 2154.9441 2 20 22 22
T370; T376 98.78; 89.93 99.99; 92.7 100; 92.96
IRQNTREHPSTANTVDR 366-382 2234.9105 2 25
T370; S375; T376 100; 99.99; 99.91
QNTREHPSTANTVDR 368-382 1805.7926 1 29 21 42
T370 100 100 100
QNTREHPSTANTVDR 368-382 1885.7590 1 14 13 14
T370; S375 98.87; 99.85 100; 99.3 99.89; 99.08
TNHQLENLEAETAPLP 383-398 1776.8763 0 38 70 58 60
List of MOP receptor peptides and phosphopeptides identified by nanoLC–MS/MS and their corresponding Mascot ion score in each condition. Below the Mascot score, phosphoRS site probability (%) is
given for each phosphorylated amino acid position (bold numbers). Positions are indicated for the canonical protein (P42866).
Table 2 C-terminal isoforms of mouse MOP.
Alignment of MOP splice variant sequences. UniProtKB/Swiss-Prot identifiers are given in Supplementary Table S1. Isoforms predicted not to contain the HA-tag have been omitted. Only portions of the
sequence containing MS-identified peptides or putative splice variant alternative peptides are shown. *, fully conserved part of the sequence. In green, peptides are identified by nanoLC–MS/MS. In blue,
other putative splice variant peptides that could have been detected by MS. Highlighted in gray, trypsin cleavage sites. Highlighted in red, phosphorylated residues identified by nanoLC–MS/MS.
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rabbit polyclonal phosphosite-specific µ-opioid receptor anti-
bodies anti-pT370 (7TM0319B), anti-pT376 (7TM0319D) and
anti-pT379 (7TM0319E) were obtained from 7TM Antibodies
(Jena, Germany)24,30,31. The polyclonal phosphosite-specific anti-
pS375 was obtained from Cell Signaling (Frankfurt, Germany).
The polyclonal rabbit phosphorylation-independent-antibody for
MOP1D was generated by S.S. the founder and scientific advisor
of 7TM Antibodies GmbH, Jena, Germany against the alternative
C-terminal splice sequence NHQRNEEPSS. This sequence cor-
responds to amino acids 384-393 of the postulated MOP1D
mouse receptor. The antibodies were affinity-purified against
their immunizing peptide using the SulfoLink kit (Thermo Sci-
entific, Rockford, IL). In addition, the following commercially
available secondary antibodies were used: polyclonal donkey anti-
rabbit IgG Cy3 (Dianova, Hamburg, Germany) and goat anti-
rabbit IgG, HRP-linked antibody (Cell Signaling, Frankfurt,
Germany).
Immunoprecipitation of HA-MOP from brain lysates.
Depending on the experiment, mice were either treated with
agonists, antagonists, saline or received no treatment. Mice were
Fig. 4 Canonical HA-MOP immunodepletion experiment. a Schematic representation of the experimental procedure. b, c (Upper panel) Depletion of HA-
MOP by several immunoprecipitation steps with either. b HA-tagged magnetic beads or (c) UMB-3-protein-A beads-conjugate. b, c (Lower panel) Dilution
series of a single HA-IP sample. Results were quantified using ImageJ and Prism software. Representative results from three independent experiments are
shown. The position of molecular mass markers is indicated on the left (in kDa). *Non-specific antibody band in c. Blots are representative of eight
independent experiments.
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anesthetized with isoflurane, killed by cervical dislocation, and
brains were quickly dissected, excluding the cerebellum. Brain
samples were immediately frozen in liquid nitrogen. Brains were
transferred to ice-cold detergent buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), containing
protease and phosphatase inhibitors), homogenized, and cen-
trifuged at 14,000 × g for 30 min at 4 °C. The supernatant was
then precipitated with HA-tagged magnetic beads (ThermoFisher
Scientific, Germany) for 60 min at 4 °C. Afterward, the receptor
beads conjugates were separated from the supernatant using a
special magnetic device (DynaMagTM−2, life technologies) and
washed three times. Proteins were eluted from the beads with SDS
sample buffer for 25 min at 43 °C and then resolved on 8%
SDS–polyacrylamide gels. After electroblotting, membranes were
incubated with anti-pT370, anti-pS375, anti-pT376, or anti-
pT379 antibody, followed by detection using a chemilumines-
cence detection system. Blots were subsequently stripped and
incubated again with the phosphorylation-independent anti-
bodies anti-HA and UMB-3 to confirm equal loading of the gels.
Films exposed in the linear range were then densitized using
ImageJ 1.37v.
The same procedure was used for the MOP1D detection
experiments. Membranes were incubated with either anti-
MOP1D or UMB-3 antibodies, followed by detection using a
chemiluminescence detection system. Blots were subsequently
stripped and incubated again with the phosphorylation-
independent antibody anti-HA to confirm equal loading of
the gels.
Immunodepletion of canonical HA-MOP. In order to enrich
MOP variants that are alternatively spliced at the C terminus, we
employed immunodepletion experiments. Brains were dissected
from untreated HA-MOP mice, homogenized as described above
and supernatants were pooled. Using the well-characterized
antibody UMB-3, receptor proteins containing the canonical
carboxyl-terminal 387LENLEAETAPLP398 motif were succes-
sively removed by immunoprecipitation using protein-A-agarose
beads. In theory, only MOP variants with non-canonical C ter-
mini should thus remain in the lysate but should be detectable
using their N-terminal HA-tag. A total of seven successive rounds
of immunoprecipitation were performed and an aliquot was
removed after each step. From each aliquot, remaining HA-MOP
was precipitated using HA-beads as described and captured
proteins were analyzed by western blot probing for HA-epitopes.
The quantitative capacity of anti-HA to precipitate HA-MOP was
evaluated using the same immunodepletion strategy. Brain lysates
were treated as described above and successively immunopreci-
pitated using HA-beads for seven rounds. Aliquots from each step
were analyzed by western blot. Proteins were then loaded in a
dilution series from 100 to 0.6% on 8% SDS–polyacrylamide gel.
Staining intensities from these blots were used as a calibration
standard to evaluate remaining HA-tagged proteins in the
immunodepletion experiments.
Cell culture and transfection. HEK293 (human embryonic kid-
ney 293 cells) cells were obtained from the German Resource
Centre for Biological Material (DSMZ, Braunschweig, Germany)
and grown in Dulbecco’s modified Eagle´s medium supplemented
with 10% fetal calf serum in a humidified atmosphere containing
5% CO2. Cells were transfected with plasmid encoding murine
HA-tagged MOP or MOP1D using Lipofectamine according to
the instructions of the manufacturer (Invitrogen, Carlsbad, CA).
Stable transfectants were selected in the presence of 1 µg ml−1
puromycin for HA-MOP or G-418 500 µg ml−1 for HA-MOP1D.
HEK293 cells stably expressing MOP were characterized using
radioligand-binding assays, western blot analysis, immunocy-
tochemistry, and cAMP assays as described previously6. For
western blot analysis, cells were seeded onto poly-L-lysine-coated
60 mm dishes and grown to 90% confluence. Cells were lysed in
RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM
EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS)
containing protease and phosphatase inhibitors (Complete mini
and PhosSTOP; Roche Diagnostics, Mannheim, Germany).
PierceTM HA-epitope tag Antibodies (Thermo Scientific, Rock-
ford, USA) were used to enrich HA-tagged MOP. To elute pro-
teins from the beads, the samples were incubated in an SDS
sample buffer for 25 min at 43 °C. Supernatants were separated
from the beads, loaded on 8% SDS–polyacrylamide gels, and
immunoblotted onto nitrocellulose afterward. After blocking,
membranes were incubated with either MOP1D antibody or
UMB-3 antibody at 4 °C overnight. On the next day, membranes
were incubated with peroxidase-conjugated secondary antibody
followed by detection using a chemiluminescence system (90 mM
p-coumaric-acid, 250 mM luminol, 30% hydrogen peroxide).
Afterward, blots were stripped and reprobed with an anti-HA
Fig. 5 Western blot analysis of MOP1D expression in vivo. a Schematic
representation of the experimental procedure b HEK293 cells stably
expressing HA-MOP1D, as well as brain lysates from HA-MOP mice, were
immunoblotted with anti-MOP1D antibody (left panel), UMB-3 (central
panel), or anti-HA antibody (right panel). Representative data from one of
four independent experiments are shown. Positions of molecular mass
markers are indicated on the left (in kDa). Blots are representative of four
independent experiments.
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antibody to confirm equal loading of the gel. Protein bands on
western blots were exposed to X-ray films.
Immunohistochemistry. Mice were anesthetized with isoflurane
and transcardially perfused with Tyrode’s solution followed by
Zamboni’s fixative (4% paraformaldehyde and 0.2% picric acid in
0.1 M phosphate buffer, pH 7.4). Brains were rapidly dissected
and postfixed in the same solution for 2 hours. Then the tissue
was cryoprotected by immersion in 10% sucrose, followed by 30%
sucrose for 48 h at 4 °C before sectioning using a freezing
microtome. Free-floating sections (40 µm) were washed multiple
times, blocked, and incubated with anti-HA antibody (Cell Sig-
naling, Frankfurt, Germany) overnight. On the following day,
Cy3-conjugated anti-rabbit antibody (Dianova, Hamburg, Ger-
many) was used for detection. Cy3 was imaged with excitation at
568 nm using a Zeiss LSM510 META laser scanning confocal
microscope or a Zeiss LSM 900 Airyscan 2 equipped with ZEN
software for image analysis.
In-gel tryptic digestion, nanoLC–MS/MS analysis, and data-
base searches. For mass spectrometry (MS) analysis, HA-
immunoprecipitated samples were reduced for 30 min at 37 °C
by adding 1×SDS sample buffer containing 30 mM DTT, and
then alkylated in 90 mM iodoacetamide for 30 min in the dark at
room temperature. A volume of 60 µl of reduced/alkylated pro-
tein samples was separated by SDS-PAGE on 10% polyacrylamide
gels followed by gel staining with colloidal Coomassie blue. A
band was excised at the level of the smear detected by western
blot and subjected to in-gel tryptic digestion using modified
porcine trypsin (Promega, France) at 20 ng µl−1. Tryptic peptides
were extracted and analyzed in triplicate by online nanoLC using
an Ultimate 3000 system (Dionex, Amsterdam, The Netherlands)
coupled to an ETD-enabled LTQ Orbitrap Velos mass spectro-
meter (ThermoFisher Scientific, Bremen, Germany) as previously
described26,32. Survey scan MS was performed in the Orbitrap
over a 300–2000 m/z mass range with resolution set to a value of
60,000 at m/z 400. The 20 most intense ions per survey scan were
selected for subsequent CID (collision-induced dissociation)/ETD
(electron transfer dissociation) fragmentation, and the resulting
fragments were analyzed in the linear trap (LTQ). The settings for
the data-dependent decision tree-based CID/ETD method were as
follows: ETD was performed instead of CID if charge state was 3
and m/z < 650, or if the charge state was 4 and the m/z < 900, or if
the charge state was 5 and the m/z < 950. The ETD was per-
formed for all precursor ions with charge states > 5. The nor-
malized collision energy was set to 35% for CID. The reaction
time was set to 100 ms and supplemental activation was enabled
for ETD. Dynamic exclusion was employed within 30 s to prevent
repetitive selection of the same peptide. For internal calibration,
the 445.120025 ions was used as lock mass. Three to four tech-
nical replicates were performed for each condition. All raw MS
files were processed with Proteome Discoverer software (version
2.1, ThermoFisher Scientific) for database search with the Mascot
search engine (version 2.6.0, Matrix Science, London, UK)
combined with the Percolator algorithm (version 2.05) for PSM
search optimization and the phosphoRS algorithm (version
3.1,33) for phosphorylation site localization. For both fragmen-
tation techniques, the parameters set for the creation of the peak
lists were: parent ions in the mass range 300–5000 Da and no
grouping of MS/MS scans. The non-fragmented filter was used to
simplify ETD spectra with the following settings: the precursor
peak was removed within a 4 Da window, charged reduced pre-
cursors were removed within a 2 Da window, and neutral losses
from charged reduced precursors were removed within a 2 Da
window (the maximum neutral loss mass was set to 120 Da). Peak
lists were searched against SwissProt database with taxonomyMus
musculus (16761 sequences) implemented with the mouse HA-
tagged MOP receptor sequence and the sequences of 19 predicted
MOP isoforms produced by alternative splicing already described
in the UniProt entry. Enzyme specificity was set to trypsin/P and a
maximum of three missed cleavages were allowed. Carbamido-
methylation of cysteine was set as fixed modification whereas
oxidation of methionine and phosphorylation of serine, threonine,
and tyrosine were set as variable modifications. Mass tolerances in
MS and MS/MS were set to 10 ppm and 0.6 Da, respectively.
Mascot results were validated by the target-decoy approach using
a reverse database of the same size. The Percolator algorithm was
used to calculate a q-value for each peptide-spectrum match
(PSM), peptides and PSM were validated based on Percolator
q-values at a False Discovery Rate (FDR) set to 5%. Then, peptide
identifications were grouped into proteins according to the law of
parsimony and filtered to 5% FDR.
Statistics and reproducibility. Western blot data were analyzed
using ImageJ and all calculations were performed using Graph-
Pad Prism software (GraphPad Software, Inc., San Diego, CA).
Wherever appropriate, data were analyzed using unpaired t-tests
with significance set at P < 0.05. Responses to cumulative doses of
morphine were analyzed by two-way ANOVA, followed by
Bonferroni’s post hoc test34–38.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the paper and its supplementary information files. All Mass spectrometry data are
available to ProteomeXchange via the PRIDE database. The data that support the
findings of this study are available from the authors upon reasonable request.
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